FLT3 and acute myeloid leukemia: Treatment of newly diagnosed AML patients with K00135, an ATP-competitor of Pim kinases, leads to decreased cell viability in AML cells independent of FLT3-ITD, while the viability of normal, human cord blood cells was unchanged [88].